Zollinger-Ellison syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:
Medical therapy for Zollinger-Ellison syndrome may includes the following:<ref name="wikipedia">Zollinger-Ellison syndrome 2015.https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome</ref>
Medical therapy for Zollinger-Ellison syndrome may includes the following:<ref name="wikipedia">Zollinger-Ellison syndrome 2015.https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome</ref>
*[[Proton pump inhibitor]]s
*[[Proton pump inhibitor]]s
:*[[Omeprazole]]
:*[[Omeprazole]] 60 mg per day
:*[[Lansoprazole]])
:*[[Esomeprazole]] 120 mg per day
:*[[Lansoprazole]] 45 mg per day <ref name="pmid15645403">{{cite journal| author=Hirschowitz BI, Simmons J, Mohnen J| title=Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. | journal=Clin Gastroenterol Hepatol | year= 2005 | volume= 3 | issue= 1 | pages= 39-48 | pmid=15645403 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15645403  }} </ref>
:*[[Rabeprazole]]] 60 mg per day
:*[[Pantoprazole]] 120 mg per day <ref name="pmid16423003">{{cite journal| author=Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W et al.| title=Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. | journal=Aliment Pharmacol Ther | year= 2006 | volume= 23 | issue= 3 | pages= 437-44 | pmid=16423003 | doi=10.1111/j.1365-2036.2006.02762.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16423003  }} </ref>
*[[H2-receptor antagonist]]s
*[[H2-receptor antagonist]]s
:*[[Famotidine]]
:*[[Famotidine]]

Revision as of 22:31, 17 July 2017

Zollinger-Ellison syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Zollinger-Ellison syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Zollinger-Ellison syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Zollinger-Ellison syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Zollinger-Ellison syndrome medical therapy

CDC on Zollinger-Ellison syndrome medical therapy

Zollinger-Ellison syndrome medical therapy in the news

Blogs on Zollinger-Ellison syndrome medical therapy

Directions to Hospitals Treating Zollinger-Ellison syndrome

Risk calculators and risk factors for Zollinger-Ellison syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Pharmacologic medical therapies for Zollinger-Ellison syndrome include proton pump inhibitors, H2-receptor antagonists, chemotherapy, and hormonal therapy.

Medical Therapy

Medical therapy for Zollinger-Ellison syndrome may includes the following:[1]

  • Octreotide can be used to slow down acid secretion

References

  1. Zollinger-Ellison syndrome 2015.https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome
  2. Hirschowitz BI, Simmons J, Mohnen J (2005). "Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study". Clin Gastroenterol Hepatol. 3 (1): 39–48. PMID 15645403.
  3. Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W; et al. (2006). "Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions". Aliment Pharmacol Ther. 23 (3): 437–44. doi:10.1111/j.1365-2036.2006.02762.x. PMID 16423003.

Template:WH Template:WS